The CDC is closely monitoring a significant uptick in cases of Mycoplasma pneumonia, commonly known as "walking pneumonia", particularly in the pediatric population across the US. This follows reports that healthcare facilities have been to see greatly increased numbers of respiratory tract infections associated with this bacterium in recent months.
Children, especially those between the ages of 2 to 4, have seen a surge in infection rates, with the CDC data indicating a rise in diagnoses of M. pneumoniae in emergency settings from 1.0 percent to 7.2 percent since late spring. Similarly, cases among older kids, ages 5 to 17, have climbed from 3.6 percent to 7.4 percent, as per the report published by Houston Chronicle. It should be noted that this increase is particularly notable given that historically, this age group was not the most affected by this type of infection.
The persistence of these levels into the fall suggests that the spread is not slowing down. M. pneumoniae is a bacteria that can lead to damage in the respiratory tract, presenting a range of symptoms from fever and sore throat to more severe manifestations like pneumonia—dubbed 'walking pneumonia' because it is often milder and doesn't necessarily confine patients to bed rest. The CDC estimates some 2 million infections each year associated with M. pneumoniae in the United States alone.
Regarding the spread of this infection, Dr. Alexis Monique Javier from Memorial Hermann shared in an interview with ABC13, "Mycoplasma pneumonia is spread through respiratory droplets." As such, prevention can largely hinge on public health basics like frequent handwashing, wearing a mask if sick, and to properly cover while coughing or sneezing.
The CDC is urging healthcare providers to actively test for M. pneumoniae while also keeping an eye out for signs of antibiotic resistance. The primary treatment option for such infections are macrolides, an alternative class of antibiotics, since the bacteria are naturally resistant to others commonly used for bacterial illnesses. These developments emphasize the importance of both prevention and the need for vigilant monitoring within the healthcare community to manage the rise of 'walking pneumonia' cases among our youngest demographic.
